力大圖書
力 大 醫 學 圖 書 網          www.leaderbook.com.tw          歡迎使用  國民旅遊卡!!
帳號 密碼
加入會員 | 首頁 | 服務 | 行銷回應 | 代訂 | 購物車 | 預訂清單
  
Search
      圖書搜尋

 - 進階搜尋
  代訂書籍
  加購書籍專區
Classes
      圖書類別
藝FUN券使用須知
國民旅遊卡使用須知
購買注意事項
力大中文圖書
橘井文化系列叢書
免疫風濕科
內分泌科
內科(家醫科及實証醫學)
婦產科
眼科
病理科(檢驗科)
外科
耳鼻喉科(聽力和語言治療)
泌尿科
胸腔內科(重症醫學)
胸腔外科
腫瘤科(血液科)
放射腫瘤科
麻醉科(疼痛科)
獸醫科
神經外科
神經內科
小兒科
心臟內科
心臟外科
急診科
感染科
放射線科
核子醫科
牙科(口腔外科)
皮膚科(醫學美容)
精神科
胃腸科
骨科
腎臟科
整形外科
藥劑科
護理科
復健科(運動醫學)
食品營養
限量特價專區
SPRINGER庫存出清專區
解剖學(組織學)
基礎醫學科
醫學系列書籍
醫學模型
醫學掛圖
Dr. gorden Plot

 - 關於力大
 - 會員專區
 - 訂單狀況
 - 行銷回應
 - 代訂書籍

 

                                                
  - 您 可 以 信 任 的 醫 學 圖 書 智 庫 

新書介紹




www.leaderbook.com.tw

Pulmonary Infection in the Immunocompromised Patient: Strategies for Management
-胸腔內科(重症醫學)
- 編號: 0-0000000004703195779
- 作者:Carlos Agusti
- 原價-5500 - (熱賣價)4500 - 節省 ↓18%

- 加入購物車

推薦指數:
- 內容介紹
Pulmonary Infection in the Immunocompromised Patient: Strategies for Management
Carlos Agusti (Editor), Antoni Torres (Co-Editor)
ISBN: 978-0-470-31957-4
Hardcover
458 pages
March 2009
The immuno-compromised patient is more susceptible to a broader range of infections than others, and infections of the respiratory tract are among the first and most common to be encountered.
In this book the authors review current options for management for a group of patients that present unique challenges to the clinician, and for whom the choices of effective therapy are often limited.

Most up to date book available dedicated specifically to this topic
Major management issue in respiratory medicine for critical care, transplant and cancer patients
Reviews important new advances in therapeutics, including drug resistance
List of Contributors.

Preface.

1. Lung Immune Defences in the Immunosuppressed Patient (Naimish Patel and Henry Koziel).

1.1 Introduction.

1.2 Host defence function in health.

1.3 Host defence function in select immunocompromised patients.

1.4 Summary and future directions for this field.

2. Microbiological Diagnosis of Respiratory Infections in the Immunocompromised (Margareta Ieven).

2.1 Introduction.

2.2 HIV infection and Mycobacterium tuberculosis.

2.3 HIV infection and Non Tuberculous Mycobacteria.

2.4 HIV and Pneumocystis jirovecii.

2.5 Infections in transplant patients or other immunodeficiencies.

2.6 Concluding remarks.

3. Diagnosis of Pneumonia in Immunocompromised Patients (Robert P. Baughman and Elyse E. Lower).

3.1 Introduction.

3.2 Clinical assessment.

3.3 Blood cultures.

3.4 Sputum.

3.5 Endotracheal aspirate.

3.6 Non bronchoscopic bronchoalveolar lavage.

3.7 Protected brush sample (PBS).

3.8 Bronchoalveolar lavage (BAL).

3.9 Transbronchial biopsy (TBB).

3.10 Surgical lung biopsy (SLB).

3.11 Sample processing.

3.12 Clinical approach to pulmonary infiltrates in immunosuppressed patient.

3.13 Conclusion.

4. Pulmonary Imaging in Immunocompromised Patients (Tom s Franquet).

4.1 Pulmonary infections in immunocompromised patients.

4.2 Respiratory infections.

4.3 Interventional procedures in patients with pneumonia.

4.4 Summary.

5. Pulmonary Infections in HIV Patients in the Highly Active Antiretroviral Therapy Era (Natividad Benito and Asunci¢n Moreno-Camacho).

5.1 Introduction.

5.2 Epidemology and etiology.

5.3 Diagnosis.

5.4 Prognosis.

5.5 Conclusions.

6. Neutropenia (Maria J. Rping, J"rg J. Vehreschild, Santiago Ewig, and Oliver A. Cornely).

6.1 Introduction.

6.2 Management of the neutropenic patient.

6.3 Specific infectious diseases.

7. General Management of Suspected Pneumonia in the Solid Organ Transplant Paitent (Andrew F. Shorr).

7.1 Introduction.

7.2 Epidemiology.

7.3 Differential diagnosis and non-infectious complications.

7.4 Diagnostic approach.

7.5 Conclusion.

8. Respiratory Infections Following Haematopoietic Stem Cell Transplantation (Ayman O. Soubani).

8.1 Immune system recovery after HSCT.

8.2 Bacterial pneumonia.

8.3 Invasive pulmonary aspergillosis.

8.4 Cytomegalovirus.

8.5 Community respiratory viruses.

8.6 Non-infectious pulmonary complications.

8.7 Conclusion.

9. Chronic Non-infectious Pulmonary Complications in Haematopoietic Stem Cell Transplantation (Bekele Afessa and Steve G. Peters).

9.1 Introduction.

9.2 Bronchiolitis Obliterans (BO).

9.3 Bronchiolitis Obliterans organizing pneumonia (BOOP).

9.4 Idiopathic pneumonia syndrome (IPS).

9.5 Diffuse alveolar haemorrhage (DAH).

9.6 Peri-engraftment respiratory distress syndrome (PERDS).

9.7 Delayed pulmonary toxicity syndrome (DPTS).

9.8 Pulmonary cytolytic thrombi (PCT).

9.9 Other non-infectious pulmonary complications.

9.10 Summary.

10. Pulmonary Infections in Patients on Chronic Glucocorticoid Treatment (Ana Ra¤¢ and Carlos Agust¡).

10.1 Introduction.

10.2 Associated inflammatory response in pneumonia.

10.3 Glucocorticoids: mechanisms of action.

10.4 Glucocorticoid therapy in clinical practice.

10.5 Diagnostic approach.

10.6 Empirical treatment of suspected pneumonia in patients receiving chronic GC therapy.

10.7 Prognosis.

10.8 Conclusions.

11. Intensive Care Management in the Immunocompromised Patient with Pulmonary Infiltrates (Gilles Hilbert, Didier Gruson, and Frederic Vargas).

11.1 Introduction.

11.2 Invasive ventilation.

11.3 Rationale for NIV.

11.4 Mechanisms of improvement with NIV in immunocompromised patients with acute respiratory failure.

11.5 Clinical studies.

11.6 Equipment and techniques: particularities in immunocompromised patients.

11.7 Predictive factors of NIV outcome.

11.8 Conclusions.

12. Current Strategies and Future Directions in Antibacterial Treatment (Jan Jelrik Oosterheert and Andy I.M. Hoepelman).

12.1 Introduction.

12.2 Farmacokinetics and farmacodynamics.

12.3 Antibacterial treatment options.

12.4 Resistance.

12.5 HIV related bacterial pulmonary infections.

12.6 Length of treatment.

12.7 Conclusions.

13. Current Strategies in the Treatment of Fungal Infections in the Intensive Care Unit Setting (Mitchell Goldman and George A. Sarosi).

13.1 Introduction.

13.2 Antifungal therapies.

13.3 The endemic fungi in the critical care unit.

13.4 Other yeast infections in the critical care unit.

13.5 Invasive mould infections in the critical care unit.

13.6 Summary.

14. Current Strategies and Future Directions in Cytomegalovirus (CMV) Pneumonitis (Julio C. Medina and Jos‚ M. Aguado).

14.1 Effects of CMV infection in immunocompromised patients.

14.2 Pathophysiology of CMV pneumonitis.

14.3 Risk factors for CMV pneumonitis.

14.4 Pulmonary manifestations of CMV infection.

14.5 Indirect respiratory effects of CMV infection.

14.6 Diagnosis of CMV pneumonitis.

14.7 Antiviral agents against CMV.

14.8 Treatment of CMV pneumonia.

14.9 Prevention of CMV pneumonia.

15. Antiviral Agents against Respiratory Viruses (Michael G. Ison).

15.1 M2 inhibitors.

15.2 Neuraminidase inhibitors.

15.3 Cidofovir.

15.4 Ribavirin.

15.5 Investigational agents.

Index.








└ 返回上一頁
      圖書搜尋         本網站購物機制使用 SSL+ 加密技術,請放心購物 Safe100%

| 加入會員 | 回首頁 | 服務中心 | 行銷回應 | 購物須知 | 會員條款 | 關於力大 | 權益申明 | 合作對象 |

本站內容為 力大圖書有限公司 所有,未經同意,請勿任意引用轉載
電話:(02)2733-2592 傳真:(02)2732-5743 E-mail:service@leaderbook.com.tw
力大圖書:台北市和平東路二段90巷2號4樓之2  台中分店:臺中榮總婦幼大樓1F
Copyright 2002-2010 LeaderBook CO.,LTD All rights reserved.